Business
Endonovo Therapeutics Awarded Preliminary Injunction Against Kodiak Capital et al
Endonovo Therapeutics Awarded Preliminary Injunction Against Kodiak Capital et al.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n \n \n Endonovo Therapeutics Awarded Preliminary Injunction Against Kodiak Capital et al\n \n \nEndonovo Therapeutics Awarded Preliminary Injunction Against Kodiak Capital et al\n\nCompany Seeks a Permanent Injunction Against Sale, Lending, Hypothecating or Transfer of Freely-Traded Unpaid for Shares\n\n \n LOS ANGELES, CA--(Marketwired - Jun 23, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) (\"Endonovo\" or the \"Company\"), a developer of bioelectronic medicine and therapies, announced it has been awarded a preliminary injunction by the Superior Court of California, County of Los Angeles, against Kodiak Capital, BMA Securities and COR Clearing, preventing the aforementioned parties from selling, transferring, hypothecating or otherwise touching or disposing of unpaid for shares tendered under the Equity Purchase Agreement (the \"EPA\") with Kodiak Capital. The preliminary injunction affirms a previously granted temporary restraining order placed on over 1.89 million shares of freely traded shares of common stock.\n \"We now have a preliminary injunction preventing the possible use of these unpaid for shares manipulating the market for our common stock,\" stated Endonovo Chairman and CEO, Alan Collier. \"We intend to continue pursuing our rights through this lawsuit to protect our shareholders' value. We have brought this lawsuit to seek the cancellation or return of these unpaid shares to the Company and for other damages. We believe that success in these efforts will increase the likelihood of securing a larger round of financing and ensure a transparent market for our common stock thus preserving shareholder value.\"\n Mr. Collier went on to say, \"The Company intends to learn if these unpaid shares were utilized to manipulate the market price of our stock. Further, we plan to judiciously pursue our legal remedies to ensure our shareholders do not incur any damages and our stock price returns to appropriate levels.\"\n About Endonovo Therapeutics\n Endonovo Therapeutics, Inc. is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine. Endonovo's Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation, cell death and the promotion of regeneration. ...